Because TP53 is located on 17p it could be assumed that the differences in expression between i17q positive and negative tumors are due to dosage effects alone, and thus the differences of expression could be a “passenger effect” of the tumor despite the fact that i17q-negative tumors are also likely suppressing TP53 via mutation, epigenetics, or other means [26,50]. Here, TP53 is linked to neoplasm.